Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.

Gilead Sciences Inc. company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Its products include Truvada, Viread, Atripla, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, amphotericin B liposome injection to treat serious invasive fungal infections; Flolan, an injected medication for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension; and Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS).Gilead Sciences Inc. company also offers Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms; and Cicletanine, which is being evaluated for the treatment of pulmonary arterial hypertension. Gilead Sciences has operations in North America, Europe, and Australia. The company has research collaborations with Abbott Laboratories, Inc.; Novartis Institutes for BioMedical Research, Inc.; Novartis Vaccines and Diagnostics, Inc.; Genelabs Technologies, Inc.; Achillion Pharmaceuticals, Inc.; Japan Tobacco, Inc.; Parion Sciences, Inc.; LG Life Sciences, Ltd.; and University of Texas System. It also has commercial collaborations with Astellas Pharma, Inc.; Emory University; F. Hoffmann-La Roche, Ltd.; Pfizer, Inc.; Dainippon Sumitomo Pharma Co., Ltd.; OSI Pharmaceuticals, Inc.; GlaxoSmithKline, Inc.; Japan Tobacco, Inc.; and Bristol-Myers Squibb Company.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Grifols' focus is on producing plasma derivatives (plasma proteins for therapeutic use). This business generates about 70% of the group's annual revenue. Its diagnostic division manufactures devices, instrumentation, and reagents for clinical analysis labs, and markets products and equipment for blood banks. The third line of business, the hospital division, develops pharmaceutical products and medical devices used in hospital pharmacies. Clients include health care professionals and patients in more than 90 countries. Nearly three-quarters of Grifols' total sales come from international markets.

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn® is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.

GTx, Inc. company was founded in 1997 and is headquartered Memphis, Tennessee. GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial.GTx it also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTx's preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc.; MacroArray Technologies, LLC; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN.

Halozyme Therapeutics, Inc. company was founded in 1998 and is based in San Diego, California. Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (Matrix) for the endocrinology, oncology, dermatology and drug delivery markets The Company's products are based on the property covering the family of human enzymes known as hyaluronidases. The Company has two marketed products: HYLENEX, a product used as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids, and Cumulase, a product used for in vitro fertilization (IVF). The Company has partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. (Roche), to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets, and with Baxter Healthcare Corporation (Baxter), to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID.

Hana Biosciences, Inc. company was founded in 2002 and is based in South San Francisco, California. Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. The company develops Optisome encapsulated formulation product candidates and a supportive care product candidate. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. Its Optisome encapsulated formulation product candidates include Marqibo, a vincristine sulfate liposomes injection for the treatment of adult acute lymphoblastic leukemia and metastatic uveal melanoma; Brakiva, a topotecan liposomes injection for the treatment of solid tumors, including small cell lung cancer and ovarian cancer; and Alocrest, a vinorelbine liposomes injection, which is used in the treatment of non-small cell lung cancer. The company's supportive care product candidate comprises Menadione Topical Lotion, a novel supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, which are used in the treatment of lung, colon, head and neck, and pancreatic cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.